Journal article

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, Susan L Neuhausen, Stephen Fox, Beth Y Karlan, Gillian Mitchell, Paul James, Darcy L Thull, Kristin K Zorn, Natalie J Carter, Katherine L Nathanson, Susan M Dornchek, Timothy R Rebbeck, Susan J Ramus, Robert L Nussbaum, Olufunrnilayo I Olopade, Johanna Rantala, Sook-Yee Yoon, Maria A Caligo Show all

Breast Cancer Research | BIOMED CENTRAL LTD | Published : 2016

Grants

Awarded by National Cancer Institute


Awarded by Research Council of Lithuania


Awarded by Spanish Association against Cancer


Awarded by RTICC


Awarded by AIRC


Awarded by Cancer Research UK


Awarded by University of Kansas Cancer Center


Awarded by German Cancer Aid


Awarded by Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI)


Awarded by GOA


Awarded by ISCIII (Spain)


Awarded by Helsinki University Hospital Research Fund, Academy of Finland


Awarded by Dutch Cancel Society


Awarded by Netherlands Organization of Scientific Research


Awarded by Pink Ribbon


Awarded by BBMRI


Awarded by Dutch Cancer Society


Awarded by Transcan


Awarded by Cancer


Awarded by Hungarian research


Awarded by Norwegian EEA Financial Mechanism


Awarded by ISCIIRETIC


Awarded by IHCC


Awarded by National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea


Awarded by NIH, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by U.S. Department of Defense Ovarian Cancer Idea award


Awarded by MH CZ - DRO


Awarded by State Budget of the Czech Republic


Awarded by Charles University in Prague


Awarded by Intramural Research Program of the National Cancer Institute,


Awarded by Russian Federation for Basic Research


Awarded by SEABASS: Ministry of Science, Technology and Innovation Ministry of Higher Education and Cancer Research Initiatives Foundation


Awarded by Malaysia Ministry of Science, Technology and Innovation, Ministry of Higher Education


Awarded by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by University Pennsylvania National Instiutes of Health (NIH)


Awarded by American Cancer Society Early Detection Professorship


Awarded by National Center for Advancing Translational Sciences (NCATS)


Awarded by European Community's Seventh Framework Programme


Awarded by National Institutes of Health


Awarded by Post-Cancer GWAS initiative


Awarded by U.S. Department of Defense



Awarded by National Institute for Health Research


Funding Acknowledgements

BCFR: This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government or the BCFR. BCFR-AU: Acknowledge Maggie Angelakos, Judi Maskiell, Gillian Dite and Helen Tsimiklis. BCFR-NY: We thank members and participants in the New York site of the Breast Cancer Family Registry for their contributions to the study. BCFR-ON: We thank members and participants in the Ontario Familial Breast Cancer Registry for their contributions to the study. BFBOCC-LT is partly supported by Research Council of Lithuania grant LIG-07/2012. We acknowledge Vilius Rudaitis and Laimonas Griskevicius. BIDMC is supported by the Breast Cancer Research Foundation. BRICOH: SLN was partially supported by the Morris and Horowitz Families Endowed Professorship. CBCS: This work was supported by the NEYE Foundation. CNIO: This work was partially supported by Spanish Association against Cancer (AECC08), RTICC 06/0020/1060, FISPI08/1120, Mutua Madrilena Foundation (FMMA) and SAF2010-20493. We thank Alicia Barroso, Rosario Alonso and Guillermo Pita for their assistance. COH-CCGCRN: City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry, supported in part by award number RC4CA153828 (JNW, principal investigator) from the National Cancer Institute and the Office of the Director, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CONSIT TEAM: Funds from Italian citizens who allocated the 5 x 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT institutional strategic projects '5 x 1000') to SM and from FiorGen Foundation for Pharmacogenomics to LP. LO is supported by AIRC (IG12780). VS is supported by FIRC (triennial fellowship "Mario e Valeria Rindi"). We acknowledge Maria Grazia Tibiletti of the Ospedale di Circolo-Universita dell'Insubria, Varese, Italy. CORE: The CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. SH is supported by an NHMRC program grant (to GCT). ACA is a Cancer Research UK senior cancer research fellow. GCT is an NHMRC senior principal research fellow. DEMOKRITOS: This research has been co-financed by the European Union [European Social Fund (ESF)] and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA. Investing in knowledge society through the European Social Fund. DKFZ: The DKFZ study was supported by the DKFZ. EMBRACE is supported by Cancer Research UK grants C1287/A10118 and C1287/A11990. DGE and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester, UK. The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE and Elizabeth Bancroft are supported by Cancer Research UK grant C5047/A8385.RE is also supported by NIHR support of the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. RE is supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. FCCC: The authors acknowledge support from The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. AKG was funded by 5U01CA113916, R01CA140323, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. We thank Ms. Jo Ellen Weaver and Dr. Betsy Bove for their technical support. GC-HBOC: The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant 110837 to Rita K. Schmutgler) and by the Center for Molecular Medicine Cologne (CMMC). GEMo: The study was supported by the Ligue Nationale Contre le Cancer; the Association "Le cancer du sein, parlors-enl" Award; the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer program and the trench National Institute of Cancer (INCa). Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study: National Cancer Genetics Network "UNICANCER Genetic Group", France. We thank all the GEMO collaborating groups for their contribution to this study. DEMO Collaborating Centers are Coordinating Centres: Unite Mixte de Genetique Constitutionnelle des Cancers Frequents, Hospices Gyms de Lyon - Centre Leon Berard, & Equipe Genetique du cancer du sein", Centre de Recherche en Cancerologie de Lyon: Olga Sinilnikova dagger, Sylvie Nlazoyer, Francesca Damiola, Laure Barjhoux, Carole Verny-Pierre, Melanie Leone, Nadia Boutry-Kryza, Alain Calender, Sophie Grand; and Service de Genetique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Etienne Rouleau, Lisa Golmard, Agnes Collet Virginie Moncoutier, Cedrick Lefol, Muriel Belotti, Antoine de Pauw, Camille Elan, Catherine Nogues, Emmanuelle Fourme Anne-Marie Birot. Institut Gustave Roussy,Villejuif Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Batasille Centre Jean Perrin, Clerrnont-Ferrand: Yves-Jean Bignon, Nancy Uhrhammer. centre Leon Berard, Lyon: Christine Lasset, Valerie Bonadona, Sandrine Handallou. Centre Francois Baclesse, Caen: Agnes Hardouin, Pascaline Berthet, Dominique Vaur, Laurent Castera. Institut Paoli Calmettes, Marseille: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi Audrey Remenieras, Francois Eisinger. CHU Arnaud-de-Villeneuve, Montpellier: Isabelle Coupier, Pascal Pujol. Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joelle Fournier, Francoise Revillion PhilippeVennint dagger, Claude Adenis. Centre Paul Strauss, Strasbourg: Daniele Muller, Jean-Pierre Fricker. Institut Bergonie, Bordeaux: Emmanuelle Barouk-Simonet, Francoisc Bonn I, Bubien, Nicolas Sevenet, Michel Longy. Institut Claudius Regaud, Toulousee: Christine Tor la Rosine Guimbaud, Laurence Gladieff, Viviane Feillel. CHU Grenoble: Dominique Leroux Helene Dreyfus, Christine Rebischung, Magalie Peysselon. CHU Dijon: Fanny Coron, Laurence Faivre. CHU St-Etienne: Fabienne Prieur, Marine Lebrun, Caroline Kientz. Hotel Dieu Centre Hospitalier, Chambery: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice: Marc Frenay CHU Limoges: Laurence Venat-Bouvet. CHU Nantes: Capucine Delnatte. CHU Bretonncau, Tours: Isabelle Mortemonsque.Groupe Hospitalier Pitie-Salpetriere, Pals: Florence Coulet, Chrystelle Cobs, Florent Soubrier, Mathilde Warcoin. CHU Vandoeuvre-les-Nancy Johanna Sokolowska, Myriam Bronner CHU Besancon: Marie-Agnes Collonge-Rame, Alexandre Damette. Creighton University, On NE, USA Henry T. Lynch, Carrie L. Snyder. Georgetown University: CI received support from the Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008), the Fisher Center for Familial Cancer Research, and Swing for the Cure. G-FAST: Kim De Leeneer is supported by GOA glaint BOF10/GOA/019 (Ghent University) and spearhead financing of Ghent University Hospital. We thank the technical support of IIse Coene en Brecht Crombez. was supported by a grant RD12/00369/0006 and 12/00539 from ISCIII (Spain), partially supported by European Regional Development FEDER funds. We acknowledge Alicia Tosar for her technical assistance. HEBCS was financially supported by the Helsinki University Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation. HEBCS thanks Taru A. Mu amen, Drs. Carl Blomqvist and Kirsimari Aaltonen and RNs Irja Erkkila and Virpi Palola for their help with the HEBCS data and samples. HERON is supported by the Dutch Cancel Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grant 110005 and the BBMRI grant NWO 184.021.007/CP46. HEBON thanks the registration teams of the Comprehensive Cancer Centre Netherlands and Comprehensive Centre South (together the Netherlands Cancer Registry) and PALGA (Dutch Pathology Registry) for part of the data collection. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HERON) consists of the following collaborating centres: coordinating centre: Netherlands Cancer Institute, Amsterdam, the Netherlands: M. A. Rookus, F. B. L. Hogervorst F. E. van Leeuwen, S. Verhoef, M. K Schmidt, N. S. Russell, J. L. de Lange, R. Wijnands; Erasmus Medical Center, Rotterdam, the Netherlands:1 M. Collee A. M. W. van den Ouweland, M. J. Floc ning, C. Seynaeve, C. H. M. van Deurzen, I. M. Obdeijn; Leiden University Medical Center, the Netherlands: C. J. van Asperen, J. T. Wijnen, R. A. E. M. Tollenaar, P. Devilee, T. C T. E. F. van Cronenburg; Radboud University Nijmegen Medical Center, the Netherlands: C. M. Kets, A. R. Mensenkamp; University Medical Center Utrecht, the Netherlands: M. G. E. M. Ausems, R. B. van der Luijt, C. C. van der Pol; Amsterdam Medical Center, Amsterdam, the Netherlands: C. M. Aalfs, T. A. M. van Os; VU University Medical Center, Amsterdam, Amsterdam, the Netherlands: j. J. P. Gille, Q. Waisfisz, H University Hospital Maastricht, the Netherlands: E. B. Gomez-Garcia M. J Blok; University Medical Center (Groningen, the Netherlands: J.C Oosterwijk, A. H. van der Hout, M. J. Mourits, G. H. de Bock; -File Netherlands Foundation for the detection of hereditary tumours, Leiden, the Netherlands: H. F. Vasen; The Netherlands Comprehensive Cancer Organization (IKNL): S. Siesling, J. Verloop; The Dutch Pathology Registy (PALGA): L. I. H. Overbeek. The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088 NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46 and the Transcan grant JTC 2012 Cancer 12-054. HEBON thanks the registration teams of IKNL. and PALGA for part of the data collection.HRBCP is supported by The Hong Kong Hereditary Breast Cancer Family Registry and the Dr. Ellen Li Charitable Foundation, Hong Kong. We, the thank Hong Kong Sanatorium and Hospital for their continual support HUNBOCS: Hungarian Breast and Ovarian Cancer Study was supported by Hungarian research grants KTA-OTKA CK-80745, OTPA K-112228 and the Norwegian EEA Financial Mechanism Hu0115/NA/2008-3/OP-9. We thank the ilungarian Breast and Ovarian Cancer Study Group members Gangs Papp, Tibor Vaszko Aniko Bozsik, Timea Pocza, Judit Franko, Maria Balogh, Gabriella Domokos, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest Hungary) and the clinicians and patients for their contributions to this study. HVH: We, thank the Oncogcnetics Group (VHIO), and the High Risk and Cancer Prevention Unit of the University Hospital Vall d'Hebron. ICO: Contract grant sponsor: Asociacion Espanola Contra el Cancer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia. contract grant numbers: ISCIIRETIC RD06/0020/1051, RD12/0036/008 PI10/01422, PI10/00748, PI13/00285, PIE13/00022, 2009SGR290 and 2014SGR364. We thank the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella. The IHCC was supported by Grant PBZ_KBN_122/P05/2004. The ILUH group was supported by the Icelandic Association "Walking for Breast Cancer Research" and by the Landspitali University Hospital Research Fund. IOVHBOCS is supported by Minister() della Salute and "5x1000" Istituto Oncologico Veneto grant. IPOBCS: This study was part supported by Liga Portuguesa Contra o Cancro. We thank Drs. Ana Peixoto, Catarina Santos, Patricia Rocha and Pedro Pinto for their skilful contribution to the study. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia; We, thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and. staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study [which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institutes of Health (USA)] for their contributions to this resource, and the many familles who contribute to kConFab. KOIIBRA is supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea (1020350). MAYO is supported by NIH grants CA116167, CA128978 and CA176785, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret rein Family Foundation and the Ting Tsung and We Fong Chao Foundation. MODSQUAD was supported by MH CZ - DRO (MMCI, 00209805) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO,CZ.1.05./21.00/03.0101) to LF, and by Charles University in Prague project UNCE204024 (to MZ).MODSQUAD acknowledges ModSQuaD members Csilla Szabo (National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA) and Michal Zikan, Petr Pohlreich and Zdenek Kleibl (Oncogynecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic). MSKCC is supported by grants from the Breast Cancer Research Foundation, the Robert. and Kate Niehaus Clinical Cancer Genetics Initiative, and the Andrew Sabin Reserch Fund. NCI: The research of MHG and PLM was supported by the Intramural Research Program of the National Cancer Institute, 711, and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc., Rockville, MD, USA. NNPIO: This work has been supported by the Russian Federation for Basic Research (grants 13-04-92613, 14-04-93959 and 15-04-01744). OCGN: We thank members and participants in the Ontario Cancer Genetics Network for their contributions to the study. OSUCCG is supported by The Ohio State University Comprehensive Cancer Center. Leigha Senter, Kevin Sweet, Caroline Craven and Michelle O'Conor were in in accrual of study participants, ascertainment of medical records and database management. Samples were processed by the OSU Human Genetics Sample Bank. PBCS: This work was supported by the ITT (Istituto Toscano Tumori) grants 2011-2013. SEABASS: Ministry of Science, Technology and Innovation Ministry of Higher Education (UMC/HIR/MOHE/06) and Cancer Research Initiatives Foundation. We thank Yip Cheng Har, Nur Aishah Mohd Talb, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBrCa Study for assistance in patient recruitment, data collet on and sample preparation. In addition, we thank Philip lau, Sng Jen-Hwei and Sharifah Nor Akmal for contributing samples from the Singapore Breast Cancer Study and the HUKM-HKL Study, respectively. The Malaysian Breast Cancer Genetic Study is funded by resarch grants from the Malaysia Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HIR/MOHE/06) and charitable funding from Cancer Research Initiatives Foundation. SWE-BRCA collaborators are supported by the Swedish, Cancer Society. Swedish, scientists participating as SWE-BRCA collaborators are as follows: from Lund University and University Hospital: angstrom ke Borg, Hakan Olsson, Helena Jemstrom, Karin Henriksson, Katja Harbst, Maria Soller, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Ofverholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelle Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, Johanna Rantala; from Umea University Hospital: Beatrice Melin, Christina Edwinsdotter Ardnor, Monica Emanuelsson; from Uppsala University: Hans Ehrencrona, Maritta Hellstrom Pigg, Richard Rosenquist; from Linkoping University Hospital: Marie Stenmark-Askmalm, Sigrun Liedgren. The University of Chicago is supported by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Womens Can Research Alliance and the Breast Cancer research Foundation. OIO is an American Cancer Society clinical research professor.We thank Cecilla Zvocec, Qun Niu, physicians, genetic counsellors, research nurses anti staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to Our program. UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center. We thank the following genetic counsellors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart Robin Lee, Amie Blanco and Peggy Conrad. Thanks are also extended to Ms. Salina Chan for her data management. UKFOCR was supported by a project grant from CRUK to Paul Pharoah. We thank Paul Pharoah, Simon Gayther Susan Ramus, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions to the UKFOCR. University Pennsylvania National Instiutes of Health (NIH) (grants R01-CA102776 and R01-CA083855); Breast Cancer Research Foundation; Susan G. Komen Foundation forte Cure, Basser Research Center for BRCA. UPITT/MWH: Frieda G. and Saul F. Shapira BRCA-Associated Cancer Research Program; Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation Geoffrey Lindeman, Marion Harris, Martin Delatyki of the Victorian Familial Cancer Trials Group.;Ale thank Sarah Sawyer and Rebecca Driessen for assembling this data and Ella Thompson for performing all DNA amplification. WCP: BYK is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and National Center for Advancing Translational Sciences (NCATS) grant UL1TR000124. Funding for the ICOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA146112 - the GAME-ON Initiative), the U.S. Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation and the Ovarian Cancer Research Fund.